COMPANY PROFILE | SUMMARY DESCRIPTION | REFERENCE |
1
STRATEGY AND ANALYSIS | 1.1 CEO statement | CEO Review |
1.2 Key impacts, risks and opportunities | Priority Action Planning |
2
ORGANISATIONAL
PROFILE | 2.1 Name of the organisation | Corporate information |
2.2. Primary brands, products | Our resources, skills and capabilities/Medicines |
2.3 Operational structure of the organization | Business organisation |
2.4 Location of the organization’s headquarters | Director’s report/
Introduction/AstraZeneca in brief |
2.5 Number of countries where organization operates | Director’s report/
Introduction/AstraZeneca in brief |
2.6 Nature of ownership and legal form | Shareholder information |
2.7 Scale of organization | Director’s report/ Introduction/AstraZeneca in brief
Shareholder information
Consolidated statement of recognized income and expense
Geographical review
Employee costs and share option plans for employees |
2.8 Significant changes during the reporting period regarding size, structure, or ownership | Research and development/ Externalisation and new opportunities |
2.9 Location of changes in operations incl facilities opening / closing | Supply and manufacturing/Cost efficiency |
2.10 Awards received during the reporting period | Local implementation |
3
REPORT
PARAMETERS | 3.1 Reporting period | Reporting performance |
3.2 Reporting cycle | Reporting performance |
3.3 Contact point for questions | Contact us |
3.4 Report Scope and Boundary | Reporting performance/Data and scope |
3.5 Process for defining report content, including: | Priority action planning/Identifying the CR priorities |
3.6 Process for defining report content, including: - Prioritizing topics within the report
| Priority action planning |
3.7 Process for defining report content, including:Identifying stakeholders the organization expects to use the report. | Engaging stakeholders
Reporting performance |
3.8 Boundary of the report | Reporting performance/Data and Scope |
3.9 State of any specific limitations | Reporting performance/General comment on the safety, health and environment (SHE) data |
3.10 Basis of reporting on joint initiatives | Reporting performance/Data and Scope |
3.11 Data measurement techniques | Reporting performance/General comment on the safety, health and environment (SHE) data |
3.12 Explanation of the effect of any re-statements | Reporting performance/General comment on the safety, health and environment (SHE) data |
3.13 Significant changes from previous reporting period | Reporting performance/General comment on the safety, health and environment (SHE) data |
4
GOVERNANCE
STRUCTURE | 4.1 Governance structure | Business organisation
Corporate governance and managing risk
Governance, management and measurement |
4.2 Independent chair of governance body | Operation of the Board of Directors |
4.3 Number of independent members of governance body | Operation of the Board of Directors |
4.4 Mechanisms for shareholders and employees to provide recommendations or direction to the highest governance body. | Independence of the Directors under the UK Combined Code |
4.5 Linkage between executive compensation and highest governance body | Directors’ remuneration report |
4.6 Processes to resolve conflict of interests | Communication and consultation/Confidential helpline
Corporate governance: Other matters/Shareholder communications |
4.7 Qualifications and expertise of the members of governance board | Board of Directors |
4.8 Internally developed statements of mission or values, codes of conduct, and principles relevant to economic, environmental, and social performance and the status of their implementation | Goals, strategy and performance
Policies and principles
Code of Conduct |
4.9 Procedures of the highest governance body for overseeing economic, environmental and social performance | Governance, management and measurement |
4.10 Processes for evaluating the highest governance body's own performance | Operation of the Board of Directors |
4.11 How is the precautionary principle addressed by organisation | Patient safety
Pharmaceuticals in the Environment
Policies and principles |
4.12 Externally developed economic, env and social charters | Memberships and charters |
4.13 Membership associations | Memberships and charters |
4.14 Stakeholder groups engaged by organisation | Engaging stakeholders |
4.15 Identification and selection of stakeholders | Engaging stakeholders |
4.16 Approaches to stakeholder engagement | Engaging stakeholders |
4.17 Key topics of concern from stakeholders | Engaging stakeholders
Priority action planning/Identifying CR priorities |